Hepatotoxicity in drug development: Detection, significance antf solutions

Journal of Hepatology

Volumn 26, Issue SUPPL.2, 1997, Pages 26-36

  Ballet, François ^a  

^a SANOFI   (France)

Author keywords

Drug development; Hepatotoxicity

Indexed keywords

ANTILIPEMIC AGENT; CHOLINESTERASE INHIBITOR; CYPROTERONE ACETATE; ENOXACIN; ETHINYLESTRADIOL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEVINOLIN; PHENOBARBITAL; SEX HORMONE;

CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALS; DRUG INDUSTRY; HUMANS; LIVER; PROTEIN BINDING;

EID: 0030993661     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(97)80494-1     Document Type: Article

References (67)

1. Spilker B. Multinational Pharmaceutical Companies. Principle and Practices, 2nd edn. New York: Raven Press, 1994.
2. Demain AL. New applications of microbial products. Science 1983; 219: 709-14.
3. Balandrin MF, Klocke JA, Wurtele ES, Bollinger WH. Natural plant chemicals: sources of industrial and medicinal materials. Science 1985; 228: 1154-60.
4. Houghten RA, Pinilla C, Blondelle SE, Appel JR, Cooley CT, Cuervo JH. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 1991; 354: 84-6.
5. Kuntz ID. Structure-based strategies for drug design and discovery. Science 1992; 257: 1078-82.
6. Bendele RA. Safety assessment program for US regulatory agencies: a perspective of requirements and compliance. Toxicol Pathol 1994; 22: 95-104.
7. Johns PA. An examination of the drug review process within the United States. J Am Coll Toxicol 1994; 13: 121-42.
8. Di Masi JA. Risks, regulation and rewards in new drug development in the United States. Regul Toxicol Pharmacol 1994; 19: 228-35.
9. Klaassen CD, Eaton DL. Principle of toxicology. In: Amour MA, Doull J, Klaassen CD, eds. Casarett and Doull's Toxicology. The Basic Science of Poisons, 4th edn. New York: Pergamon Press, 1991; 12-49.
10. Lumley C. Clinical toxicity: could it have been predicted? Premarketing experience. In: Lumley CE, Walker SR, eds. Animal Toxicity Studies. Their Relevance for Man. Lancaster: Quay Publishing, 1990; 49-57.
11. Lumley CE, Walker SR. Predicting the safety of medicines from animal toxicity tests. I. Rodents alone. Arch Toxicol 1987; Suppl 11:295-9.
12. Lumley CE, Walker SR. Predicting the safety of medicines from animal toxicity tests. II. Rodents and non-rodents. Arch Toxicol 1987; Suppl 11: 300-4.
13. Spriet-Pourra C, Auriche M. Drug Withdrawal from Sales, 2nd edn. Richmond: PJB Publications Ltd, 1994.
14. Zbinden G. Predictive value of animal studies in toxicology. Regul Toxicol Pharmacol 1991; 14: 167-77.
15. Tomaszewski KE. Application of animal toxicology data to clinical study of experimental drugs. Comp Haematol Int 1993; 3: 67-70.
16. Broom C. Design of first-administration studies in healthy man. In: O'Grady J, Linet OI, eds. Early Phase Drug Evaluation in Man. London: Macmillan Press, 1990; 206-13.
17. Parkinson C, Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Human Exp Toxicol 1993; 12: 99-109.
18. Zbinden G. The concept of multispecies testing in industrial toxicology. Regul Toxicol Pharmacol 1993; 17: 85-94.
19. Guillouzo A, Guguen-Guillouzo C Eds. Isolated and cultured hepatocytes. Paris: Editions INSERM and John Libbey Eurotext, 1986.
20. Azri S, Gandolfi AJ, Brendel K. Precision-cut liver slices: an in vitro system for profiling potential hepatotoxicants. In Vitro Toxicol 1990; 3: 309-25.
21. Fisher R, Brendel K, Hanzlik RP. Correlation of metabolism, covalent binding and toxicity for a series of bromobenzene derivatives using rat liver slices in vitro. Chem Biol Interact 1993; 88: 191-208.
22. Dean JH, Olson HM. The integration of investigative toxicology in the drug discovery process. Biol Cell 1993; 77: 3-8.
23. Kapeghian JC, Traina VM. The role of experimental toxicology in safety evaluation: challenges facing the pharmaceutical industry. Med Res Rev 1990; 10: 271-80.
24. Thibault N, Ballet F. Effect of bile acids on intra-cellular calcium in isolated rat hepatocyte couplets. Biochem Pharmacol 1993; 45: 289-93.
25. Thibault N, Maurice M, Maratrat M, Cordier A, Feldmann G, Ballet F. Effect of tauroursodeoxycholate on actin filament alteration induced by cholestatic agents: a study in isolated rat hepatocytes couplets. J Hepatol 1993; 19: 367-76.
26. Thibault N, Claude JR, Ballet F. Actin filament alteration as a potential marker for cholestasis: a study in isolated rat hepatocyte couplets. Toxicology 1992; 73: 269-79.
27. Monks TJ, Lau SS. Reactive intermediates and their toxicological significance. Toxicology 1988; 52: 1-53.
28. Hinson JA, Roberts DW. Role of covalent and non covalent interactions in cell toxicity: effect on proteins. Annu Rev Pharmacol Toxicol 1992; 32: 471-510.
29. Nelson SD, Pearson PG. Covalent and non covalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol 1990; 30: 169-95.
30. Boelsterli UA. Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab Rev 1993; 25: 395-451.
31. Pumford NR, Myers TG, Davila JC, Highet RJ, Pohl LR. Immunochemical detection of liver protein adducts of the non-steroidal antiinflammatory drug diclofenac. Chem Res Toxicol 1993; 6: 147-50.
32. Bartolone JB, Sparks K, Cohen SD, Khairallah EA. Immunochemical detection of acetaminophen-bound liver proteins. Biochem Pharmacol 1987; 36: 1193-6.
33. Bartolone JB, Birge RB, Sparks K, Cohen SD, Khairallah EA. Immunochemical analysis of acetaminophen covalent binding to proteins. Partial characterization of the major acetaminophen-binding liver proteins. Biochem Pharmacol 1988; 37: 4763.
34. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 1994; 7: 434-42.
35. Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.
36. Pessayre D. Mechanisms of drug-induced hepatic injury. In: Stricker BHCH, ed. Drug-induced Hepatic Injury, 2nd edn. Amsterdam: Elsevier, 1992; 23-51.
37. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species differences. Drug Metab Dispos 1993; 21: 874-82.
38. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46: 13-20.
39. Mc Donald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, et al. Preclinical evaluation of lovastatin. Am J Cardiol 1988; 62: 16J-27J.
40. Kornbrust DJ, Mc Donald JS, Chennekatu PP, Duchai DM, Stubbs RJ, Germershausen JI, et al. Toxicity of the HMGcoenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharm Exp Ther 1989; 248: 498-505.
41. Schulte-Hermann R. Induction of liver growth by xenobiotic compounds and other stimuli. CRC Crit Rev Toxicol 1974; 3: 97-158.
42. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453-8.
43. Green S. Nuclear receptors and chemical carcinogenesis. Trends Pharmacol Sci 1992; 13: 251-5.
44. Poellinger L, Gottlicher M, Gustafsson JA. The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands. Trends Pharmacol Sci 1992; 13: 241-4.
45. Huff J, Lucier G, Tritscher A. Carcinogenicity of TCDD. Experimental, mechanistic and epidemiological evidence. Annu Rev Pharmacol Toxicol 1994; 34: 343-72.
46. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IFH. Mechanistically-based human hazards assessment of peroxisome proliferators-induced hepatocarcinogenesis. Hum Exp Toxicol 1994; 13, Suppl 2: S1-S117.
47. Reddy JK, Lalwai ND. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 1983; 12: 1-58.
48. Yager JD, Shi YE. Stimulation of hepatocyte DNA synthesis by ethinyl estradiol. In: Butterworth BE, Slaga TJ, Farland W, McClain M, eds. Chemically Induced Cell Proliferation. Implication for Risk Assessment. New York: Wiley-Liss, 1991; 53-65.
49. Yager JD, Zurlo J, Sewall C, Lucier GW, He H. Growth stimulation followed by growth inhibition in liver of female rats treated with ethinyl estradiol. Carcinogenesis 1994; 15: 2117-23.
50. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281: 577-92.
51. Shaw IC, Jones HB. Mechanisms of non-genotoxic carcinogenesis. Trends Pharmacol Sci 1994; 15: 89-93.
52. Purchase IFH. Current knowledge of mechanisms of carcinogenicity: genotoxins versus non-genotoxins. Hum Exp Toxicol 1994; 13: 17-28.
53. Bayly AC, Roberts RA, Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopine. J Biol Cell 1994; 125: 197-203.
54. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992; 13: 245-51.
55. Goldsworthy TL, Butterworth BE, Maronpot RR. Concepts, labelling procedures and design of cell proliferation studies relating to carcinogenesis. Environ Health Perspect 1993; 101, suppl 5: 59-66.
56. Diaz D, Fahre I, Daujat M, Fahre G, Joyeux H, Bories P, Michel H, Maurel P. The gastric antisecretory drug omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-47.
57. Mc Guire EJ, Gray RH, De La Iglesia FA. Chemical structure-activity relationships: peroxisome proliferation and lipid regulation in rats. J Am Coll Toxicol 1992; 11: 353-61.
58. Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH. Peroxisome proliferation and non genotoxic carcinogenesis: commentary on a symposium. Fundam Appl Toxicol 1991; 16: 233-48.
59. Lock EA, Mitchell AE, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol 1989; 29: 145-63.
60. McClain RM. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Path 1989; 17: 294-306.
61. Barter RA, Klaassen CD. UDP-glucuronyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. Toxicol Appl Pharmacol 1992; 113: 36-42.
62. Boobis AR, Sesardic D, Murray BP, Edwards RJ, Singleton AM, Rich KJ, et al. Species variation in the response of the cytochrome P450 dependent monooxygenase system to inducers and inhibitors. Xenobiotica 1990; 20: 1139-61.
63. Foley J, Ton T, Maronpot RR, Butterworth B, Goldworthy TL. Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferating hepatocytes in rats. Environ Health Perspect 1993; 101, suppl 5: 199-206.
64. Dietrich DR, Candrian R, Marsman DS, Popp JA, Kaufmann WK, Swenberg JA. Retrospective assessment of liver cell proliferation via PCNA: a comparison with tritiated thymidine. Cancer Lett 1994; 79: 45-51.
65. Soames AR, Lavender D, Foster JR, Williams SM, Wheeldon EB. Image analysis of bromodeoxyuridine (BrdU) stain-ing for measurement of S-phase in rat and mouse liver. J Histochem Cytochem 1994; 42: 939-44.
66. Goldworthy TL, Morgan KT, Popp JA, Butterworth BE. Guidelines for measuring chemically induced cell proliferation in specific rodent target organs. In: Butterworth BE, Slaga TJ, Farland N, McClain M, eds. Chemically Induced Cell Proliferation. Implication for Risk Assessment. New York: Wiley-Liss, 1991; 253-4.
67. Scheuplein RJ. Use of cell proliferation data in cancer risk assessment: FDA view. Environ Health Perspect 1993; 101, suppl 5: 139-42.